Preclinical studies have verified that IL-18 TRUCKs CAR-T cells targeting GD2 induced monocytes recruitment, which helped reprogram the tumor stroma into a more favorable environment, thus making CAR-T cell therapy for solid tumors more effective [67]. The gene discussed is IL18; the disease is neoplasm.